Curis, Inc is focused on developing innovative therapeutics for the treatment of cancer, specifically targeting hematologic malignancies and other cancers. This includes their marketed product, Erivedge, and several drugs in their pipeline.

Curis, Inc

Curis - Doctors

Curis

HSTS

Google Maps

Cloudflare CDN

Cloudflare

Cloudflare JS

CDN JS

Google Maps API

jQuery CDN

Cloudflare Bot Manager

Comcast

Chief Financial Officer & Chief Administrative Officer

Bill Steinkrauss

Claims Attorney at Curi & Co-Founder at Noble Talent Co.

Kristen Janicek

Member Board of Directors

Marc Rubin

General Counsel

Nancy Soohoo

Director of Executive & Board Services at Curi - A Medical Mutual Company

Rebekah Law

Vice President of Regulatory Affairs and Quality Assurance

Christine Guertin

VP Medical Affairs

Felix Geissler M.D., Ph.D.

Vice President Technical Operations

Frank Waligora

Business Management

Li Zhou

Vice President Clinical Operations

Marissa Volpe

James Tobin

James Dentzer

Chief Executive Officer

Felix Geissler

Kimberly Steinmann

Vice President of Clinical Development

David Tuck

Senior Vice President, Clinical & Translational Sciences

Dora Ferrari

Vice President of Clinical Operations

Chief Medical Officer

Greater Boston Area Companies (Top 10K)

New England Companies that Exited

Cambridge Health Care Companies

New England Biotechnology Companies

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its proprietary targeted cancer programs, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com.

Post-IPO Equity - Curis

Genentech

Debiopharm Group

Cambridge

Massachusetts

United States

North America

Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer

Curis to Present at Upcoming Healthcare Conferences in September

Curis to Present at Upcoming Healthcare Conference in July

Curis to Present at Upcoming Healthcare Conference in July 2024

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis shares target cut by $9, retains buy rating

Curis Announces Additional Data from TakeAim Leukemia Study

Earnings call: Curis reports on emavusertib progress in Q1 2024

Curis: Q1 Earnings Snapshot

Curis to Present Updated Data from the TakeAim Leukemia Study

South Korea

Asia

Philippines

India

Estonia

Europe

HTML5

Vimeo

DigiCert

Google Analytics

F5 NGINX

Google Fonts

Apache Server

Modernizr

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Curis Inc

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 10, 2024 10:06 AM	ee885076
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 10, 2024 10:25 AM	a32d8ca9
company summary	general
signals	general	Sep 10, 2024 10:06 AM	9e59d442
crunchbase trigger	general	Oct 28, 2024 1:50 PM	85811b7b
crunchbase profile	general	Oct 28, 2024 4:55 PM	71cb11f9
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	65218312
peers	general	Sep 10, 2024 10:06 AM	4f8a07e8
news basic	general	Sep 10, 2024 10:06 AM	0ec674fd
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:CURIS

Curis, Inc

Last Close

4.10

22/11 21:00

Market Cap

34.12M

Beta: -

Volume Today

107.98K

Avg: -